Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new way to treat advanced lung cancer by using your own immune cells, called tumor-infiltrating lymphocytes, boosted in a lab to fight your cancer. Researchers want to see if combining these special immune cells with an immunotherapy drug called nivolumab can help patients whose cancer has specific genetic changes.
You might be able to join if you are 18 or older, have advanced non-small cell lung cancer with specific genetic mutations like EGFR, ALK, ROS1, or HER2, and your cancer has grown after previous treatments. You must also be active enough to handle your daily activities and meet specific health requirements set by the study team.
First, doctors will take immune cells from your tumor and grow more of them in a lab. You will then receive chemotherapy to prepare your body, followed by an infusion of your boosted immune cells and medications like nivolumab and interleukin-2 to help those cells attack the cancer.
This study is currently recruiting participants and takes place in Tampa, Florida, in the United States. The study team will guide you through all the details regarding visits and procedures.
- 1Uses your own tumor-fighting immune cells grown in a lab
- 2Combined with an immunotherapy drug and preparation chemotherapy
- 3Designed for advanced lung cancer with specific genetic mutations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.